Annual Report


2023 was a year of challenge and change, both in the world and at Lonza. We have seen high interest rates, persistent inflation, supply chain disruptions, wars in Ukraine and the Middle East, growing geopolitical tensions, and the continuing challenges of climate change. However, corporate investments remained solid, harnessing innovation and technology to address the challenges of the future.

Albert M. Baehny
Chairman of the Board of Directors and CEO ad interim

Lonza at a Glance


(Full-time equivalent)




New CDMO programs signed


Global development and manufacturing sites


CORE EBITDA margin in %


Trademark filings


Sales in CHF




New CDMO customers


Sales growth in %1


Small2 and large3 molecules


ROIC in %


CDMO customers4


Active patent families

  1. Constant exchange rate (CER); in actual exchange rate (AER) +7.9%

  2. Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering

  3. Including mammalian, microbial, bioconjugates, drug product services and cell and gene therapy products (personalized medicines are included in pre-clinical and clinical molecules only, early development services are included for pre-clinical molecules only)

  4. Based on distinct companies

Personal Highlights

Philippe Deecke

Chief Financial Officer

Our capacity to deliver long-term value is supported by our strong balance sheet and our sustained approach to organic growth investments to meet customer needs.

Discover more

Maria Soler Nunez

Head, Group Operations

Across our site network, we deliver value for our customers through our combined focus on quality, safety and operational excellence.

Discover more

Andreas Bohrer

Group General Counsel

Sustainability is a key aspect of value creation, alongside quality and efficiency. It is integrated into our business strategy, and supported by clear delivery targets in our remuneration policies.

Discover more

Ulrike Kaeppler

Chief Human Resources Officer (CHRO)

Our people are our greatest asset. Taken together, their talent, dedication and hard work bring to life our purpose to enable a healthier world.

Discover more

Gordon Bates

President, Small Molecules Division

In Small Molecules, we continue to adapt our capabilities and commercial offerings aligned with market needs, further augmented with additional capacity to meet sustained customer demand, particularly supporting highly potent API products. Looking ahead, we will continue to focus on the acquisition of early-phase clinical projects to help drive future growth.

Discover more

Jean-Christophe Hyvert

President, Biologics Division

In Biologics, we continued to build our pipeline, strengthened our manufacturing network, in particular for ADCs, and built our technology portfolio with the acquisition of Synaffix. We signed multiple dedicated long-term customer programs, which reflect the value of our offerings. 2024 was our strongest signing year on record.

Discover more

Daniel Palmacci

President, Cell & Gene Division

In Cell & Gene, we celebrated the groundbreaking of a new cell therapy manufacturing facility in Portsmouth (US) to support the development and commercialization of the Vertex type 1 diabetes cell therapy portfolio.

Discover more

Christian Seufert

President, Capsules & Health Ingredients Division

In Capsules & Health Ingredients, we improved customer satisfaction and advanced our innovation roadmap. We advanced the development of our next-generation hard empty capsule manufacturing technology and extended our proprietary capsule sealing technology to additional polymer formulations.

Discover more

Our Businesses



Sales in CHF

Discover more

Small Molecules


Sales in CHF

Discover more

Our Businesses

Cell & Gene


Sales in CHF

Discover more

Capsules & Health Ingredients


Sales in CHF

Discover more